Monoclonal antibodies (Mabs) are highly specific, naturally evolved molecules that can recognize and eliminate pathogenic antigens and diseases.
Research on Mabs has led to the development of new therapeutic agents in the last 20 years to fight cancer, autoimmune diseases and infections. Current therapeutic Mabs are genetically modified molecules designed to ensure high specificity and activity.
Some Mabs are used to destroy malignant tumor cells and prevent tumor growth by blocking cell membrane receptors, while other Mabs are designed to neutralize molecules that allow cancer cells to survive and invade the body.
Finally, a new generation of Mabs is linked to potent payloads, either cytotoxic drugs, radionuclides, or toxins.